Our case series describes clinically meaningful responses to BRAF-targeted therapy in BRAF V600E-mutated CNS tumors, including the second published case of response to targeted therapy in BRAF-mutated RDD and a durable response of more than 5 years in a patient with BRAF-mutated ganglioglioma. Here, BRAF is linked to central nervous system neoplasm.